XML 49 R33.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2021

Employee Benefits And Share Based Compensation [Abstract]

Stock option activity was as follows:

	Number of Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
	(In thousands)			(In dollars)		(In years)		(In thousands)
Outstanding as of December 31, 2020		1,333		$	27.86
Exercised		(421	)	$	22.81
Outstanding as of December 31, 2021		912		$	30.19		6.11	$	2,487

As of December 31, 2021
Vested and expected to vest		912		$	30.19		6.11	$	2,487
Exercisable Options		717		$	30.96		5.74	$	2,008

Schedule of Ranges of Outstanding And Exercisable Stock Options

The following table summarizes significant ranges of outstanding and exercisable stock options as of December 31, 2021:

	Options Outstanding						Options Exercisable
Range of Exercise Prices	Shares Outstanding		Weighted- Average Remaining Contractual Life		Weighted- Average Exercise Price Per Share		Shares Exercisable		Weighted- Average Exercise Price Per Share
	(In thousands)		(In years)		(In dollars)		(In thousands)		(In dollars)
$18.58 - $25.37		264		4.09	$	23.43		264	$	23.43
$26.61 - $26.61		370		7.55	$	26.61		186	$	26.61
$38.32 - $41.67		278		6.12	$	41.37		267	$	41.42
$18.58 - $41.67		912		6.11	$	30.19		717	$	30.96

Schedule of RSU Activity

RSU activity was as follows:

	Number of Shares			Weighted Average Grant Date Fair Value Per Share		Weighted Average Remaining Contractual Term		Average Intrinsic Value
	(In thousands)			(In dollars)		(In years)		(In thousands)
Outstanding as of December 31, 2020		1,584		$	30.66
Granted		763		$	38.53
Vested		(645	)	$	31.65
Cancelled		(147	)	$	33.28
Outstanding as of December 31, 2021		1,555		$	33.86		1.38	$	45,414

Schedule of Performance Shares Activity

Performance shares were never granted in the years prior to 2020. Performance shares activity was as follows:

	Number of Shares		Weighted Average Grant Date Fair Value Per Share		Weighted Average Remaining Contractual Term		Average Intrinsic Value
	(In thousands)				(In years)		(In thousands)
Outstanding as of December 31, 2018		—		—
Granted		—		—
Vested		—		—
Cancelled		—		—
Outstanding as of December 31, 2019		—		—
Granted		141	$	28.22
Vested		—		—
Cancelled		—		—
Outstanding as of December 31, 2020		141	$	28.22
Granted		152	$	37.58
Vested		—		—
Cancelled		—		—
Outstanding as of December 31, 2021		293	$	33.07		2.08	$	8,559

Schedule of Weighted Average Assumptions

The following table sets forth the weighted-average assumptions used to estimate the fair value of purchase rights granted under the ESPP:

	Year Ended December 31,
	2021			2020			2019
	ESPP
Expected life (in years)		0.5			0.5			0.5
Risk-free interest rate		0.05	%		0.72	%		2.06	%
Expected volatility		40.8	%		54.8	%		43.9	%

Schedule of Total Stock-Based Compensation Expense Resulting from Stock Options, RSUs, Performance Shares and the ESPP

The following table sets forth the stock-based compensation expense resulting from stock options, RSUs, performance shares and the ESPP included in the Company’s consolidated statements of operations:

	Year Ended December 31,
	2021		2020		2019
	(In thousands)
Cost of revenue	$	2,103	$	4,091	$	2,843
Research and development		5,161		5,183		6,532
Sales and marketing		7,628		7,634		9,069
General and administrative		11,103		13,597		10,693
Total	$	25,995	$	30,505	$	29,137